Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. - Wikidata - wikimedia - TriplyDB

Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity.

Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity.

http://www.wikidata.org/entity/Q35121535

about

Genetics and biology of pancreatic ductal adenocarcinoma Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies Orchestrating the Tumor Microenvironment to Improve Survival for Patients With Pancreatic Cancer: Normalization, Not Destruction Monitoring of the Immune Dysfunction in Cancer Patients Stromal reengineering to treat pancreas cancer Chemotherapy and tumor microenvironment of pancreatic cancer.Anti-Bv8 antibody and metronomic gemcitabine improve pancreatic adenocarcinoma treatment outcome following weekly gemcitabine therapy.Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression.Molecular pathways: myeloid complicity in cancer.Pathological and molecular evaluation of pancreatic neoplasms.Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells.Attenuated Toxoplasma gondii Stimulates Immunity to Pancreatic Cancer by Manipulation of Myeloid Cell Populations.CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma.Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression.T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma.Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma C-reactive protein exacerbates renal ischemia-reperfusion injury: are myeloid-derived suppressor cells to blame?Pancreatic adenocarcinoma up-regulated factor (PAUF) enhances the accumulation and functional activity of myeloid-derived suppressor cells (MDSCs) in pancreatic cancer.Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer Role of immune cells in pancreatic cancer from bench to clinical application: An updated review Pancreatic stellate cell: Pandora's box for pancreatic disease biology.Strategies to relieve immunosuppression in pancreatic cancer.Stromal biology and therapy in pancreatic cancer: a changing paradigm.Prognostic value of programmed cell death protein 1 expression on CD8+ T lymphocytes in pancreatic cancer High immunosuppressive burden in cancer patients: a major hurdle for cancer immunotherapy.Can Targeting Stroma Pave the Way to Enhanced Antitumor Immunity and Immunotherapy of Solid Tumors?Adapting Cancer Immunotherapy Models for the Real World.Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps.Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies.Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.The pancreatic cancer microenvironment: A true double agent.Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression.Granulocytic myeloid-derived suppressor cells maintain feto-maternal tolerance by inducing Foxp3 expression in CD4+CD25-T cells by activation of the TGF-β/β-catenin pathway.Phenotypically resembling myeloid derived suppressor cells are increased in children with HIV and exposed/infected with Mycobacterium tuberculosis.Targeted activation of melanoma differentiation-associated protein 5 (MDA5) for immunotherapy of pancreatic carcinoma.Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma.Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma.Anti-α-enolase antibody limits the invasion of myeloid-derived suppressor cells and attenuates their restraining effector T cell response.

P2860

Q26765438-DC879B44-83AC-4EF4-8481-D6DD1C93A009 Q26774312-F9DAB39E-38CB-4563-A35B-8AA062124566 Q26799714-524B3BC2-C835-47AD-B4CE-4B79D7F9CC2C Q26801834-127F10C8-1320-40ED-8CC8-EA147942D6D7 Q28072712-63546D35-F7DF-4B4F-9251-0928CD0A5921 Q33827708-E231B8B7-7672-45D9-8BF6-BB4F83642AF1 Q33876637-12390313-F114-4223-BB67-8CC30698DA82 Q34346752-B451F1BC-6F20-42E2-882F-B84E0932F14E Q34417878-D6F91973-81A8-458B-8AB8-A8642611ACB5 Q34725969-5F683CF9-05D5-404D-90C6-C61ECC9DE5D2 Q35670143-1CFB26E5-5DE7-4D2E-AF9D-2745E7103D82 Q35772377-7605EB33-98F0-4C03-8664-50D13113B0CD Q35833055-ADA5A928-807D-4BAD-8B49-0E0E3485B4BD Q35920573-35D31D9E-8271-482A-90E7-D417E19CEE48 Q36041701-07190654-4CE0-4584-A396-D39D8E74377A Q36447669-9DC780BA-C250-4148-9B70-0749593A872C Q36494634-D8E03EF1-7E67-450D-B20C-D109BF55EC50 Q36661995-133C4FC5-04DC-4D80-87C0-24D4A3A39D0A Q37139474-97EA3D92-2942-4185-9712-EFAF74685F41 Q37588378-4FEA0813-CAEC-44D1-86DB-32116A42E37E Q37600068-DE5ED233-D3EE-4F3F-8290-FCE3A9DBDB21 Q37606102-9D6191A5-92A7-468E-89F7-8396F10BC7F2 Q37624480-E1187BCF-4428-4D10-84D9-7113BEFD65A7 Q38445328-8020A973-7BC7-487D-A03F-2F12D5715269 Q38494338-C2B30180-0FCC-42AB-AECB-DFC407AE651E Q38644119-498EEF24-7894-465A-A17C-E850B1594B0B Q38748299-E639D8E4-8E2C-4013-BDA9-53F87223E0BD Q38795935-BF430A06-0817-4E93-B4BC-9C80F248F8DE Q38815212-FCF0A7D3-B476-4CFB-8189-8E76584885AB Q38845812-D9745699-9CC6-4028-8CF9-DDD132921CFF Q39178061-82F25688-358B-4CDB-A548-5C62794B7F70 Q39204274-52F1E628-BA58-475E-90D3-4662E3CE0A17 Q39366753-3C73317F-537A-4922-9D82-6222AC61CA9E Q39766565-0EB6F061-7DAF-4F48-9CBC-4966575AF73A Q39888293-823C466B-F63A-44F5-99CB-462AE1474C78 Q40445818-83A33785-0163-4DD0-8F3F-57411A8095CB Q41182217-E516E012-252F-4C55-9978-7EBE93DAF244 Q41514095-99DD5015-5ABB-4568-8E3B-D3CB385C8656 Q41858851-946C813A-E214-47A7-80E6-4A1FEA7B5746 Q42082414-68762F02-20D6-4BF6-A03E-FE366EF2CD50

P2860

Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity.

http://www.wikidata.org/entity/Q35121535

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Targeted depletion of an MDSC ...... arcinoma to adaptive immunity.

@ast

Targeted depletion of an MDSC ...... arcinoma to adaptive immunity.

@en

type

label

Targeted depletion of an MDSC ...... arcinoma to adaptive immunity.

@ast

Targeted depletion of an MDSC ...... arcinoma to adaptive immunity.

@en

prefLabel

Targeted depletion of an MDSC ...... arcinoma to adaptive immunity.

@ast

Targeted depletion of an MDSC ...... arcinoma to adaptive immunity.

@en

P1433

Q35121535-9AB37122-EEFD-4F3F-8224-AF5751BE7C82

P1476

Q35121535-50CE4312-EEBB-408E-B784-89D08AA5A61C

P2093

Q35121535-103B0365-65A6-4AD8-B71D-77B088C11ADA

Q35121535-5BE3215C-4A63-4290-982F-3ADBCC087F10

Q35121535-99ADB3A7-2AA0-49D9-88BB-D3F58D739DD9

Q35121535-B2DB34EE-8A84-41F5-B729-0DA7768152BA

Q35121535-EA55D710-6AE4-4563-8DE4-CFB32644FA46

P2860

Q35121535-00524FDE-7592-4929-AC29-86F475520970

Q35121535-01131B46-A560-4266-9262-DB8DCD897998

Q35121535-0FB1C2D8-CCFC-4C25-A3A5-1FDE1090B12F

Q35121535-1AEE3071-F23D-43E4-A2B7-909F216A1962

Q35121535-2390EE1E-C108-4170-89C7-9B08643785B9

Q35121535-23A09B9D-BEE8-4F6A-871A-0D43FC8DFF8E

Q35121535-288A7EBC-94E0-48EF-B88A-938889244D9A

Q35121535-299A2C32-7555-40B6-A8A4-0A42E59E5017

Q35121535-2B15AB90-F2A3-4DFE-B005-E17830897619

Q35121535-2DA21F84-638D-453F-86A4-FCC79CAB365A

P304

Q35121535-E689638D-7D62-4186-B7F2-27959951E035

P31

Q35121535-F11789C5-8EBF-49D0-A2AB-59ACDB2549F8

P356

Q35121535-DC11DB3D-1C8E-4343-89D2-FCE23B23EB97

P407

Q35121535-4A0A38EC-8A43-447D-861D-E31ACFAA26B2

P433

Q35121535-C2630490-A2D2-4E57-8A18-878BF8BF32FB

P478

Q35121535-69D881E6-589C-404E-B30E-2008165427ED

P50

Q35121535-D96EA904-D766-48B8-8178-4BAFB087137C

Q35121535-E0D5857B-6A50-422B-9547-617EC9FB3527

Q35121535-E79AD0A7-59A4-4CE4-A332-05297582DF05

P577

Q35121535-075F5EE0-0379-464F-AF4B-1B54557882FC

P698

Q35121535-C96B90F6-170A-482A-A6F0-3158D478A2B6

P921

Q35121535-7FDA1128-2061-4AEF-A48B-7E381FC4211D

P932

Q35121535-5EB95D76-597D-4727-88DC-E68F3AADB1FD

P356

GUTJNL-2013-306271

P1433

P1476

Targeted depletion of an MDSC ...... carcinoma to adaptive immunity

@en

P2093

Ingunn M Stromnes

http://www.w3.org/2001/XMLSchema#string

J Scott Brockenbrough

http://www.w3.org/2001/XMLSchema#string

Markus A Carlson

http://www.w3.org/2001/XMLSchema#string

Philip D Greenberg

http://www.w3.org/2001/XMLSchema#string

Randi M Simmons

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer genome landscapes

Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Hematopoietic growth factors: personalization of risks and benefits

Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma

Cancer statistics, 2012

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Coordinated regulation of myeloid cells by tumours

Successful elimination of memory-type CD8+ T cell subsets by the administration of anti-Gr-1 monoclonal antibody in vivo

P304

1769-1781

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/GUTJNL-2013-306271

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

63

http://www.w3.org/2001/XMLSchema#string

P50

Sunil R Hingorani

Kamel Izeradjene

P577

2014-02-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24555999

http://www.w3.org/2001/XMLSchema#string

P921

P932

4340484

http://www.w3.org/2001/XMLSchema#string